News & Updates

Nine-month, fully oral modified short treatment regimens (mSTRs) consisting of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine or delamanid appear to yield high treatment success and good safety results in the treatment of patients with rifampicin-resistant, fluoroquinolone-susceptible tuberculosis (TB), according to a study.

The phase III NOTUS trial further validates the potential of the monoclonal antibody dupilumab in reducing exacerbations and improving lung function and quality of life (QoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation.

The inclusion of remdesivir in the SoC is significantly associated with a 54-percent lower risk of death at day 28 among hospitalized adults with COVID-19 who require O₂ support, suggests a cross-study comparison that weight-balances patients from a clinical trial with those from a real-world study

Surgical lung biopsy (SLB) neither reduces lung function nor increases the risk of death or lung transplantation in patients with idiopathic pulmonary fibrosis (IPF), reports a study.

Findings from the phase III KRYSTAL-12 trial underpin the treatment potential of adagrasib for previously treated metastatic non-small cell lung cancer (NSCLC) harbouring a KRAS^G12C mutation.

In Singapore, short-acting β2-agonist (SABA) is often overused for asthma, especially in the specialist care setting, according to data from the SABINA III study.

Undernutrition has been singled out as a potential risk factor for tuberculosis (TB) in a recent Cochrane review.

Off-label pulmonary arterial hypertension (PAH)-targeted drugs may increase long-term survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH), as shown in a study.

Outpatients with post-COVID condition (PCC) generally tolerated exercise without significant worsening of symptoms or decline in aerobic performance after 48 hours. However, they had lower muscle strength and aerobic capacity than controls, and even showed signs of POTS* and myopathy in a randomized crossover trial.